Nanoparticles | Cisplatin | ||
---|---|---|---|
Name | Effects | ||
Cerium oxide nanoparticles (CONPs | Mild tubular cloudy swelling and necrosis | • Tubular apoptosis, necrosis, intratubular eosinophilic material, and atrophy | [52] |
Nanoceria | • Inhibition of CDDP-induced kidney weight reduction after acute (14 days) and chronic (28 days) exposure, • Normal tubules | • Tubular dilation • Reduced kidney weight | [53] |
Green silver nanoparticles (CP-AgNPs) | • Tubules: mild cloudy swelling, cast formation, regenerated tubular epithelium, vacuolation • Glomeruli: few shrunken, wide Bowman’s spaces, periglomerular leukocytic infiltration | • glomerular lesions: congestion, collapse, atrophy, and necrosis • tubular lesions: necrosis of the lining epithelium, extensive vacuolation, atrophy, cystic dilatation, cast formation • Interstitium: vascular congestion, leukocytic infiltration | [54] |
N-(2-hydroxyphenyl) acetamide-conjugated gold nanoparticles (NA2-AuNPs) | • A great ameliorating effects on kidney damage scores at the dose of 25 mg/kg • Normal renal cortex, corpuscles and tubules • Protection of brush borders of proximal convoluted tubules | • Excessive epithelial vacuolization, • Glomerular atrophy • Damaged brush borders | [55] |
selenium nanoparticles (SeNPs) | • Fish oil + SeNPs + CDDP + γ-radiation group: surface blebs, swelling of tubular occasional cells, intratubular eosinophilic material | • CDDP group: Glomerular lesions: atrophy, fibrosis, thick basement membrane, wide Bowman’s space. Tubular lesions: necrosis and edema in convoluted tubules, hemorrhage • CDDP + γ-radiation group: More severe hemorrhage, glomerular atrophy, dilated tubules, leucocytic infiltration | [57] |
Tea polyphenol-functionalized SeNPs (Se@TE NPs) | Normal | • Swelling of tubular cells and glomeruli • Narrowing interstitial space | [58] |
Se@SiO2 nanocomposites | Normal | Tubular epithelial injury, inflammatory infiltration, cast formation, tubular dilatation | [60] |
A. officinarum-silver nanoparticles (AG-AO) | Normal | Tubular atrophy, necrosis, cortex and medullary damage, Interstitial edema and inflammation | [62] |
Curcumin nanoparticles | • Normal • Proximal tubular area = 1500 μm2 | • Tubular necrosis (mild to moderate), proteinaceous cast formation, • Proximal tubular area = 893 μm2 | [73] |
Curcumin nanoparticles | Normal | • Shrinkage of the glomerulus, wide Bowman’s space • Tubular atrophy, necrosis, cast formation | [72] |
Cisplatin-incorporated liposome conjugated with EGFR antibodies (EGFR:lP-cDDP) | Normal | Acute cortical tubular degeneration and regeneration | [78] |
RNAi-Chemotherapy Layer by Layer Nanoparticle | Normal | Swollen tubules | [80] |
Curcumin-Loaded Liposomes synthesized by microfluidic technology | Normal | Acute tubular necrosis, multiple necrotic cells, debris in lumen, | [83] |
Nanoparticulated honokiol | Reduced CDDP-induced histopathological changes | Inflammatory infiltration, interstitial fibrosis, tubular lesions, smaller kidneys with pale appearance, | [84] |
Lipid-coated cisplatin nanoparticles | Normal | • Collapsed glomeruli; mesangial cells fused with tubules, dilated arteries with red blood cells • Systemic injection group: collapsed Bowman’s capsule, and disappeared Bowman’s space • Local injection group: lymphocyte infiltration | [85] |
Cisplatin NanoComposite (CHIT/Cis/MgO NPs) | Normal structure with congested intertubular blood vessels and albuminous casts | • Massive intertubular hemorrhage, tubular degenerative changes, extended renal tubules, leukocyte infiltration, necrosis • Glomerular atrophy, wide Bowman’s space | [87] |
CDDP complexed with γ-polyglutamic acid and chitosan (γ-PGA/CDDP-CS) | Normal tubules, but edematous mesenchymal tissues | Damage to proximal tubules | [89] |
poly (lactic-co-glycolic acid) nanoparticles | Normal | Pathological atrophy | [96] |
PLGA-encapsulated nano-Boldine (NBol) | • Normal glomerular structure • Minimal tubular damage | Glomerular atrophy, tubular damage, dilatation of urinary space | [97] |
N, N’- diphenyl-1, 4-phenylenediamine loaded PLGA nanoparticles (Nano-DPPD) | Decreased fibrosis score and tubular injury score | Increased the scores | [98] |
Thymoquinone nanoparticles (NP THY) | • Almost normal parenchyma structure with negligible deformity of few corpuscles • Normal tubules with some luminal dilation in cortex • Infiltrated neoplastic cells: degenerated | • Disorganization of parenchyma • Atrophy and deformity of corpuscle/glomeruli • Degenerative changes in tubule lining • Epithelium: e.g., deformed small nuclei, and swollen cells • Infiltrated neoplastic cells: degenerated | [99] |
Cisplatin/cl-micelles | • After 13 days: normal • After 28 days: reduced CDDP-induced histopathological changes by regenerating tubules in cortical subcapsular region, but some change, e.g., basophilic tubules and interstitial lymphocytic infiltrate, were irreversible | • After 13 days: all animals: tubular vacuolization, basophilia; some animals: necrosis in tubules and collecting duct, and reduced cellularity in papilla | [101] |
P-quercetin | • Reduced cortical injury • No impact on medullary injury | • Massive tubular necrosis in outer medulla, and slight damage in cortical region • Tubular dilation, increased hyaline material | [105] |
Carbon monoxide (CO)-loaded hemoglobin-vesicle (CO-HbV) | Normal | • Tubular injuries: swelling and detachment | [113] |
Nanoparticles functionalized with folate (CP-FA-BSA-NPs) | Normal | • Reduced kidney weight • After 1 week: necrosis | [128] |
LHRH-modified dextran nanoparticles (Dex-SA-CDDP-LHRH) | Reduced CDDP-induced histopathological changes | • Severe necrosis in proximal tubules • Loss of tubular brush border • Thick glomerular basement membrane and mesangium | [118] |
nano-gallic acid | • At concentration of 10 mg/kg: normal • At concentration of 50 and 100 mg/kg: proximal tubule injury, infiltration of inflammatory cell and RBCs | More severe than NPs induced tubular injury and inflammatory cells infiltration | [119] |
Urolithin A nanoparticles | Reduced CDDP-induced histopathological changes | Interstitial expansion, tubular necrosis, atrophy, dilation, apoptotic bodies, casts, thicker glomerular basement membranes | [120] |
A magnetic CDDP-encapsulated nanocapsule (CDDP-PAA-NC) | Normal | Swollen proximal tubules, vacuolar degeneration/dilation, basophilic tubules in cortex | [121] |
EGFR-albumin-cisplatin nanoparticles | Normal | Tubular atrophy and cystic dilatation | [125] |
Pt (IV) prodrug-loaded ligand-induced self-assembled nanoparticles (GA-ALG@Pt NPs) | Normal | • In corticomedullary region: acute proximal tubular injury • Tubular dilation, hydropic degeneration, and protein casts | [126] |
Nanocomposites of CDDP-chitosan | • Normal glomeruli, slightly wider capsular space • Normal tubular epithelial lining | • Glomerular and tubular damages | [91] |
CaCO3 nanoparticle (CDDP/OA-LCC NPs) | • Almost normal | • Loss of brush border • Loss of epithelium • Tubular necrosis | [115] |